Curaleaf (OTCMKTS:CURLF) Shares Gap Down – Here’s Why

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)’s share price gapped down before the market opened on Monday . The stock had previously closed at $2.37, but opened at $2.21. Curaleaf shares last traded at $2.25, with a volume of 45,165 shares.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CURLF. Alliance Global Partners reaffirmed a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd. ATB Cormark Capital Markets upgraded Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd. Finally, Zacks Research raised Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Curaleaf currently has an average rating of “Buy”.

Curaleaf Price Performance

The firm has a market cap of $1.54 billion, a PE ratio of -7.57 and a beta of 0.71. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.52 and a quick ratio of 0.76. The business’s fifty day moving average is $2.45 and its 200-day moving average is $2.68.

Curaleaf (OTCMKTS:CURLF) last released its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. The firm had revenue of $333.07 million for the quarter, compared to analysts’ expectations of $328.70 million. On average, research analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.